<DOC>
	<DOCNO>NCT00766324</DOCNO>
	<brief_summary>To assess antitumor activity PHA-739358 administer IV infusion accord two different dose schedule metastatic HRPC patient progress standard , docetaxel-based 1st-line chemotherapy HRPC base PSA response , select best dose schedule investigation .</brief_summary>
	<brief_title>PHA-739358 Treatment Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Metastatic hormone refractory prostate cancer progress docetaxel base therapy Adequate bone marrow , liver kidney function More one prior chemotherapy line Uncontrolled hypertension Brain leptomeningeal disease Myocardial infarction , severe/unstable angina , symptomatic congestive heart failure , cerebrovascular accident previous 6 month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>